Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Α. Dimopoulos, Meletios; Oriol, Albert; Nahi, Hareth; F. San Miguel, Jesús; J. Bahlis, Nizar; Z. Usmani, Saad; Rabin, Neil; Z. Orlowski, Robert; Komarnicki, Mieczysław; Suzuki, Kenshi; Plesner, Torben; Yoon, Sung‐Soo; Ben Yehuda, Dina; G. Richardson, Paul; Goldschmidt, Hartmut; Reece, Donna; Lisby, Steen; Z. Khokhar, Nushmia; O’Rourke, Lisa; Chiu, Christopher; Qin, Xiang; Guckert, Mary; Ahmadi, Tahamtan; Moreau, Philippe

doi:10.1056/nejmoa1607751

Public

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Published in New England Journal of Medicine • Oct 5, 2016

Authors:

Meletios Α. Dimopoulos

Albert Oriol

Hareth Nahi

Abstract

BACKGROUND: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more p...

Subject

Daratumumab

Lenalidomide

Dexamethasone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!